{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:46:59Z","timestamp":1781498819160,"version":"3.54.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.nmd.2021.07.396","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T23:25:25Z","timestamp":1633994725000},"page":"1287-1295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Myasthenia gravis: do not forget the patient perspective"],"prefix":"10.1016","volume":"31","author":[{"given":"Nils Erik","family":"Gilhus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.G.M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Iren Bark\u00e5s","family":"Hovland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huw","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.07.396_bib0001","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0002","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nature Rev Dis Primers"},{"key":"10.1016\/j.nmd.2021.07.396_bib0003","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/WCO.0b013e3283572588","article-title":"Myasthenia and the neuromuscular junction","volume":"25","author":"Gilhus","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0004","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mus.25205","article-title":"Factors affecting outcome in myasthenia gravis","volume":"54","author":"Andersen","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/jnnp.2005.072355","article-title":"Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001","volume":"77","author":"Owe","year":"2006","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1016\/j.nmd.2021.07.396_bib0006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mus.24697","article-title":"Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark","volume":"53","author":"Hansen","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0007","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.nmd.2020.08.355","article-title":"Mortality rates and causes of death in Swedish myasthenia gravis patients","volume":"30","author":"Westerberg","year":"2020","journal-title":"Neuromusc Dis"},{"key":"10.1016\/j.nmd.2021.07.396_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Dis"},{"key":"10.1016\/j.nmd.2021.07.396_bib0009","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10072-012-1157-z","article-title":"Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years","volume":"34","author":"Huang","year":"2013","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: a systematic review","volume":"38","author":"Landfeldt","year":"2020","journal-title":"Pharmacoeconom"},{"key":"10.1016\/j.nmd.2021.07.396_bib0011","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","article-title":"Fatigue in patients with myasthenia gravis. A systematic review of the literature","volume":"30","author":"Ruiter","year":"2020","journal-title":"Neuromusc Dis"},{"key":"10.1016\/j.nmd.2021.07.396_bib0012","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","article-title":"Measuring clinical treatment response in myasthenia gravis","volume":"36","author":"Barnett","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nmd.2021.07.396_bib0013","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of MG-QoL15, resulting in slight revision and subesequent evaluation of the MG-QoL15R","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0014","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/ene.14397","article-title":"Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis","volume":"27","author":"Menon","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/mus.26695","article-title":"Cross-sectional analysis of the myasthenia gravis patient registry: Disability and treatment","volume":"60","author":"Cutter","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.nmd.2021.07.396_bib0017","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","article-title":"Gender differences in quality of life among patients with myasthenia gravis in China","volume":"18","author":"Dong","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.nmd.2021.07.396_bib0018","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0019","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12883-016-0757-2","article-title":"Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997-2011: a Danish nationwide cohort study","volume":"16","author":"Frost","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0020","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mus.26694","article-title":"Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis","volume":"60","author":"Harris","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0021","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","article-title":"Clinical features and impact of myasthenia gravis disease in Australian patients","volume":"22","author":"Blum","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0022","doi-asserted-by":"crossref","first-page":"E1617","DOI":"10.1212\/WNL.0000000000010574","article-title":"Patient-acceptable symptom states in myasthenia gravis","volume":"95","author":"Mendoza","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.396_bib0023","doi-asserted-by":"crossref","first-page":"e98089","DOI":"10.1371\/journal.pone.0098089","article-title":"A conceptual framework for evaluating Impairments in myasthenia gravis","volume":"9","author":"Barnett","year":"2014","journal-title":"Plos One"},{"key":"10.1016\/j.nmd.2021.07.396_bib0024","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mus.26069","article-title":"Fatigue is a relevant outcome in patients with myasthenia gravis","volume":"58","author":"Tran","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0025","doi-asserted-by":"crossref","first-page":"e00538","DOI":"10.1002\/brb3.538","article-title":"Fatigue in myasthenia gravis: risk factors and impact on quality of life","volume":"6","author":"Hoffmann","year":"2016","journal-title":"Brain Behavior"},{"key":"10.1016\/j.nmd.2021.07.396_bib0026","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2377-13-132","article-title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","volume":"13","author":"Elsais","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0027","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archneur.1993.00540060055018","article-title":"Coping with myasthenia gravis and implications for psychotherapy","volume":"50","author":"Doering","year":"1993","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0028","first-page":"e9184","article-title":"A review of psychiatric comorbidity in myasthenia gravis","volume":"12","author":"Law","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.nmd.2021.07.396_bib0029","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00415-020-09767-7","article-title":"Depression in myasthenia gravis: a heterogeneous and intriguing entity","volume":"267","author":"Gavrilov","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000313","article-title":"Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study","volume":"1","author":"Suzuki","year":"2011","journal-title":"BMJ Open"},{"key":"10.1016\/j.nmd.2021.07.396_bib0031","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4274\/npa.y5611","article-title":"The relationship of symptoms of anxiety and depression with disease severity and treatment modality in myasthenia gravis: a cross-sectional study","volume":"50","author":"Aysal","year":"2013","journal-title":"Noropsik Ars-Arch Neuropsych"},{"key":"10.1016\/j.nmd.2021.07.396_bib0032","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fpsyt.2019.00481","article-title":"Risk of depressive disorders following myasthenia gravis: a nationwide population-based retrospective cohort study","volume":"10","author":"Chu","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.nmd.2021.07.396_bib0033","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/ene.12439","article-title":"Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study","volume":"21","author":"Andersen","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0034","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mus.10035","article-title":"Quality of life in patients with myasthenia gravis","volume":"25","author":"Padua","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11916-018-0687-3","article-title":"Pain, Headache, and other non-motor symptoms in myasthenia gravis","volume":"22","author":"Tong","year":"2018","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.nmd.2021.07.396_bib0036","first-page":"A178","article-title":"Headache in patients with myasthenia gravis (MG)","volume":"72","author":"Nishimoto","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.396_bib0037","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s00415-006-0429-z","article-title":"Paraneoplastic diseases associated with thymoma","volume":"254","author":"Evoli","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0038","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1177\/0300060516672124","article-title":"Relationship between hearing function and myasthenia gravis: A contemporary review","volume":"45","author":"Ralli","year":"2017","journal-title":"J Internat Med Res"},{"key":"10.1016\/j.nmd.2021.07.396_bib0039","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0404.2005.00541.x","article-title":"Irreversible cochlear damage in myasthenia gravis - otoacoustic emission analysis","volume":"113","author":"Hamed","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2021.07.396_bib0040","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/mus.26850","article-title":"Myasthenia gravis patient and physician opinions about immunosuppressant reduction","volume":"61","author":"Hehir","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0041","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mus.25625","article-title":"Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis","volume":"56","author":"Machado-Alba","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0042","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0165-5728(87)90075-0","article-title":"Antibodies in sera from patients with myasthenia gravis do not bind to nicotinic acetylcholine receptors from human brain","volume":"16","author":"Whiting","year":"1987","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0043","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/mus.21478","article-title":"Determinants of cognitive impairment in elderly myasthenia gravis patients","volume":"40","author":"Marra","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0044","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10072-008-0001-y","article-title":"Neuropsychological assessment in myasthenia gravis","volume":"30","author":"Sitek","year":"2009","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0045","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00115-005-1877-x","article-title":"Intelligence, attention, and memory in patients with myasthenia gravis","volume":"76","author":"Feldmann","year":"2005","journal-title":"Nervenarzt"},{"key":"10.1016\/j.nmd.2021.07.396_bib0046","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1054\/jocn.2001.1016","article-title":"Ratings of subjective mental fatigue relate to cognitive performance in patients with myasthenia gravis","volume":"9","author":"Paul","year":"2002","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0047","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/0972-2327.156560","article-title":"Association between myasthenia gravis and cognitive function: A systematic review and meta-analysis","volume":"18","author":"Mao","year":"2015","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0048","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jns.2019.02.001","article-title":"Cognitive dysfunction in mice with passively induced MuSK antibody seropositive myasthenia gravis","volume":"399","author":"Sabres","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0049","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/mus.24556","article-title":"Impact of myasthenia gravis on family planning: How do women with myasthenia gravis decide and why?","volume":"52","author":"Ohlraun","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0050","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1212\/01.WNL.0000082725.21444.EC","article-title":"Myasthenia gravis - Consequences for pregnancy, delivery, and the newborn","volume":"61","author":"Hoff","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.396_bib0051","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","article-title":"Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group","volume":"85","author":"Norwood","year":"2014","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1016\/j.nmd.2021.07.396_bib0052","first-page":"1","article-title":"Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence","author":"Gilhus","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0053","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3389\/fneur.2020.00554","article-title":"Myasthenia gravis can have consequences for pregnancy and the developing child","volume":"11","author":"Gilhus","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0054","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-510X(98)00031-8","article-title":"Exacerbation of myasthenia gravis during the menstrual period","volume":"156","author":"Leker","year":"1998","journal-title":"J Neuroll Sci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","volume":"129","author":"Andersen","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2021.07.396_bib0056","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.nmd.2021.07.396_bib0057","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0058","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jtcvs.2019.11.052","article-title":"A systematic review of paraneoplastic syndromes associated with thymoma: Treatment modalities, recurrence, and outcomes in resected cases","volume":"160","author":"Zhao","year":"2020","journal-title":"J Thor Cardiovasc Surg"},{"key":"10.1016\/j.nmd.2021.07.396_bib0059","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","article-title":"Myasthenia gravis and infectious disease","volume":"265","author":"Gilhus","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0060","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13365-014-0303-1","article-title":"A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Chahin","year":"2015","journal-title":"J Neurovirol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0061","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia gravis and COVID-19: clinical characteristics and outcomes","volume":"11","author":"Camelo-Filho","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0062","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3389\/fphar.2020.01333","article-title":"Immunosuppressive drugs and COVID-19: a review","volume":"11","author":"Schoot","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0063","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/jnnp-2020-323565","article-title":"Management of patients with generalised myasthenia gravis and COVID-19: four case reports","volume":"91","author":"Hubers","year":"2020","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1016\/j.nmd.2021.07.396_bib0064","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/ene.12383","article-title":"Myasthenia and risk of cancer: a population-based case-control study","volume":"21","author":"Pedersen","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0065","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1468-1331.2011.03621.x","article-title":"Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study","volume":"19","author":"Liu","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0066","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jns.2009.11.006","article-title":"Extrathymic malignancies in thymoma patients with and without myasthenia gravis","volume":"290","author":"Owe","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0067","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/ane.13017","article-title":"Lifestyle factors and disease-specific differences in subgroups of Swedish myasthenia gravis","volume":"138","author":"Westerberg","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2021.07.396_bib0068","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jocn.2018.01.047","article-title":"Low serum vitamin D levels in patients with myasthenia gravis","volume":"50","author":"Kang","year":"2018","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0069","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/nu12030789","article-title":"Pathophysiological role and therapeutic implications of vitamin D in autoimmunity: focus on chronic autoimmune diseases","volume":"12","author":"Bellan","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.nmd.2021.07.396_bib0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2019.09.019","article-title":"Factors Affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody","volume":"209","author":"Apinyawasisuk","year":"2020","journal-title":"Am J Ophthalm"},{"key":"10.1016\/j.nmd.2021.07.396_bib0071","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/1756-185X.13878","article-title":"Can smoking cessation interventions reduce disease activity in persons with chronic autoimmune inflammatory diseases? A Cochrane Review summary with commentary","volume":"23","author":"Engkasan","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.nmd.2021.07.396_bib0072","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/mus.25493","article-title":"Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: a pilot study","volume":"56","author":"Westerberg","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0073","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mus.25552","article-title":"Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training","volume":"56","author":"Rahbek","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0074","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.rmed.2018.09.001","article-title":"Effects of long-term respiratory muscle endurance training on respiratory and functional outcomes in patients with Myasthenia gravis","volume":"144","author":"Freitag","year":"2018","journal-title":"Resp Med"},{"key":"10.1016\/j.nmd.2021.07.396_bib0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nmd.2020.12.004","article-title":"Physical training and exercise in myasthenia gravis","volume":"31","author":"Gilhus","year":"2021","journal-title":"Neuromusc Dis"},{"key":"10.1016\/j.nmd.2021.07.396_bib0076","first-page":"1","article-title":"Speech characteristics in individuals with myasthenia gravis: a case control study","author":"Ayres","year":"2020","journal-title":"Logoped Phoniatr Vocol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0077","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2334\/josnusd.57.161","article-title":"An update on myasthenia gravis, challenging disease for the dental profession","volume":"57","author":"Tamburrini","year":"2015","journal-title":"J Oral Sci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0078","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.clinph.2017.09.001","article-title":"Pitfalls and errors in measuring jitter","volume":"128","author":"Stalberg","year":"2017","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0079","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3390\/ijms19061677","article-title":"The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes","volume":"19","author":"Cruz","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmd.2021.07.396_bib0080","doi-asserted-by":"crossref","first-page":"e01819","DOI":"10.1002\/brb3.1819","article-title":"Epidemiology of myasthenia gravis in Sweden 2006-2016","author":"Westerberg","year":"2020","journal-title":"Brain Behav"},{"key":"10.1016\/j.nmd.2021.07.396_bib0081","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","article-title":"Seropositve myasthenia gravis: a nationwide epidemiologic study","volume":"73","author":"Heldal","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.396_bib0082","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3389\/fneur.2018.01173","article-title":"Correlation between thymus radiology and myasthenia gravis in clinical practice","volume":"9","author":"Luo","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0083","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.26096","article-title":"Thymus imaging in myasthenia gravis: The relevance in clinical practice","volume":"58","author":"Klimiec","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0084","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/RLI.0000000000000120","article-title":"Chemical-shift and diffusion-weighted magnetic resonance Imaging of thymus in myasthenia gravis Usefulness of quantitative assessment","volume":"50","author":"Priola","year":"2015","journal-title":"Invest Radiol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0085","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0086","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0087","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.396_bib0088","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00415-009-5318-9","article-title":"Unsatisfactory outcomes in myasthenia gravis: influence by care providers","volume":"257","author":"Dunand","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0089","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multi-centre study","volume":"12","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0090","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1474-4422(17)30363-0","article-title":"Eculizumab: a treatment option for mysthenia gravis?","volume":"16","author":"Gilhus","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2021.07.396_bib0091","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.07.396_bib0092","first-page":"S139","article-title":"Rituxmab in ptients with moderate to severe myasthenia gravis: a subgroup analysis of the BEATMG study","volume":"60","author":"Nowak","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.07.396_bib0093","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/mus.24608","article-title":"Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States","volume":"51","author":"Burns","year":"2015","journal-title":"Muscle Nerve"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621005836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621005836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:12:15Z","timestamp":1760775135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621005836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":93,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0960896621005836"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.07.396","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis: do not forget the patient perspective","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.07.396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}